Techsonian (press release) The company's lead product candidate is vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia or AML. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)declined -2.87% and closed at $1.69 in the last trading session with ... and more »
HealthCanal.com They also successfully targeted another antibiotic resistance gene encoding SHV-18, a mutation in the bacterial chromosome providing resistance to quinolone antibiotics, and a virulence factor in enterohemorrhagic E. coli. In addition, the researchers ... and more »
